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Concise summary
Intraepithelial neoplasia is subclassified into two
important categories: low-grade dysplasia (LGD),
including mild and moderate dysplasia; and high-
grade dysplasia (HGD), comprising severe dyspla-
sia and squamous cell carcinoma in situ. Impor-
tant studies have shown that squamous dysplasia
and carcinoma in situ were the only histological le-
sions associated with a significantly increased risk
of developing esophageal squamous cell carcinoma
(ESCC) and that increasing grades of dysplasia were
strongly associated with increasing risk, indicating
that the histological grading was clinicallymeaning-
ful.Recent advances inmolecularbiology emphasize
the strict sequence LGD–intraepithelial neoplasia–
HGD–intraepithelial neoplasia in the development
of invasive cancer, depending on genetic and epi-
genetic changes that parallel the histological mod-
ifications observed in the neoplastic progression.
In resection specimens, the overall frequency of
loss of heterozygosity (LOH) at microsatellite loci
was significantly increased as the pathological status
changed from LGD to HGD and ESCC, indicating
that tumorigenesis of the esophageal squamous ep-
ithelia is a progressive process involving a series of
molecular alterations.
In the context of Barrett’s esophagus (BE), glan-
dular dysplasia is classified into two important cat-
egories, namely LGD and HGD, on the basis of
accurate histological features and an accurate di-
agnostic interpretation from the pathologist. The
existence of the sequence LGD–HGD–invasive can-
cer is supported by immunohistochemistry (IHC)
and molecular biology. In particular, the applica-
tion of immunohistochemical techniques revealed
the existence of two pathways in the development
of dysplasia in the context of BE: on one side, dys-
plastic cells show positivity for p16 and negativ-
ity for p53 and HER2; on the other side, dysplas-
tic cells express p53 and HER2 and lack of p16
expression.
Esophageal adenocarcinoma (EAC) is primar-
ily associated with obesity, gastroesophageal reflux
disease (GERD), and BE. In GERD patients, the
low pH, as well as the bile salts, induces expres-
sion of cyclooxygenase-2 (COX-2), which catalyzes
the conversion of arachidonic acid into various
prostaglandins including prostaglandin E2 (PGE2)
and induces proliferation of Barrett’s cells, with a
high probability of these cells accumulating replica-
tion errors. PGE2 also inhibits tumor surveillance by
inhibitingnatural killer cell activity.COX-2mayalso
induce the production of reactive oxygen species
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(ROS), resulting in oxidative stress and subsequent
oxidative DNAdamage that could contribute to car-
cinogenesis. The presence of genetic mutations is
another important factor leading to EAC. Changes
in the cell cycle of the affected epithelial cells, such
as an increased number of cells in S phase, cor-
responding to DNA synthesis, and G2 phase have
been described in BE patients. Genomic instability
in BE is also represented by widespread LOH, point
mutations, alterations in microsatellite alleles, and
epigenetic changes including hypermethylation of
promoter regions in genes. Several data suggest that
interactions between risk factors may be more im-
portant than the individual risk factors themselves
in the development of EAC.
In Barrett’s mucosa, is p53-immunoreactive LGD
at higher risk than non-immunoreactive LGD for
progressing to EAC? In order to answer this ques-
tion, we have to answer two others. First, is the his-
tologic diagnosis of LGD reproducible? Second, if it
is reproducible, then is positive p53 staining of the
dysplastic epithelium a better predictor of progres-
sion to carcinoma than negative staining? Several
studies of dysplasia have found that reproducibil-
ity among even highly experienced pathologists is
best at the highest end of the dysplastic spectrum,
namely HGD and carcinoma, while it is poorest at
the LGD end. Since there is no consistent definition
of LGD, it is to be expected that the definitions in
the literature and in the textbooks of gastrointesti-
nal pathology will not be the same. p53 is a tumor
suppressor gene, a transcription factor important
in cell cycle regulation. The encoded protein is nu-
clear, so the immunostain is easy to interpret. Sev-
eral studies have shown that p53 positivity helped in
the diagnosis of LGD, and it seems that patients with
p53-immunoreactive LGDare at higher risk for pro-
gression than those with p53–non-immunoreactive
LGD, although this is clouded by the lack of repro-
ducibility for the LGD diagnosis. There is recent
mention of p53 immunostaining being considered
as an adjunct to routine histopathologic diagno-
sis, hoping to improve the diagnosis of dysplasia in
Barrett’s mucosa.
An evolving understanding of the complex glyco-
protein milieu in the normal and diseased esoph-
agus paints an intriguing picture that suggests a
re-emergent role for lectins, proteins with high sen-
sitivity, and variable specificity for selected glycosyl
moieties, in the diagnosis and management of BE
and EAC. Applying lectin-affinity chromatography
to serum samples using the fucosyl-specific lectins
Aleuria aurantia lectin and Lotus tetragonolobus ag-
glutinin, some studies identified a subset of pro-
teoglycans including fetuin B, a cystatin that is
somewhat overexpressed in Barrett’s HGD rela-
tive to disease-free esophagus, but significantly
increased in carcinoma. The relative depletion of
fucosyl residues in the BE––EAC sequence is im-
mediately applicable to routinely processed biopsy
samples. Studies using a fucosyl-specific lectin
derived from Aspergillus oryzae confirmed the ex-
pectation that decreased histochemical stainingmay
predict the transition from BE to EAC. Further
findings have led to the formulation of a robust
risk-stratification biomarker panel for progression
fromBE to EAC. Among other lectins, theN-acetyl-
d-galactosaminyl–selective agglutinin from Helix
pomatia selectively labels glycans that, when present
or increased in number,may be associatedwith pro-
gression from locally invasive esophageal disease to
metastasis. Selective lectin labeling of esophageal
mucosa in BE patients may prove to be a useful
guide for traditional biopsy techniques. As an ad-
junct to confocal laser endomicroscopy, lectin label-
ing could reasonably be expected to increase the effi-
ciency of both scanning and targeting of suspicious
lesions.
-Methylacyl-CoA-racemase (AMACR) is pres-
ent in many dysplasias and carcinomas, Dysplas-
tic mucosa may be AMACR+ with IHC, and the
question was raised whether AMACR could be of
value in identifying patients at highest risk for
BE. Cohort studies showed that, although mild
AMACR expression was associated with a trend
towards an increased risk of neoplastic progres-
sion, the risk was especially elevated with strong
AMACR expression. After adjusting for histologi-
cal diagnosis, only strong AMACR expression re-
mained associated with a significantly increased
risk of neoplastic progression. AMCR expression
has a degree of predictability, but is not sensitive,
non-dysplastic biopsies having mild and yet strong
immunoreactivity.
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Table 1. The subclassification of squamous intraepithelial neoplasia in the 2010 WHO edition
Squamous intraepithelial neoplasia (IEN)
Low-grade IEN High-grade IEN
Mild dysplasia Moderate dysplasia Severe dysplasia Squamous cell carcinoma in situ (CIS)
1. Can low-grade squamous/
intraepithelial dysplasia give rise directly
to invasive cancer?
Vincenzo Villanacci and Marianna Salemme
villanac@alice.it
The development of dysplasia in the squamous
esophageal epithelium has been extensively investi-
gated by several authors in the literature, emphasiz-
ing the role of alcohol consumption, smoking, and
diet (in particular the ingestion of N-nitroso com-
pounds) as main risk factors for the onset of dys-
plastic morphological changes.1 In the latest WHO
classification edition (2010), the term intraepithe-
lial neoplasia (IEN) was introduced and subclassi-
fied into two important categories: low-grade IEN
(LG-IEN), including mild and moderate dysplasia,
and high-grade IEN (HG-IEN), comprising severe
dysplasia and squamous cell carcinoma in situ (CIS;
Table 1).2 Histologically, squamous IEN is defined
by both architectural and cytological abnormali-
ties that vary in extent and severity (Fig. 1). These
include loss of normal cell polarity, overlapping nu-
clei, and lack of surface maturation. Characteris-
tic cytologic features include enlarged, hyperchro-
matic nuclei with increased nuclear-to-cytoplasmic
ratio and increased mitotic activity. At low magni-
fication, a sharp demarcation commonly delineates
the neoplastic epithelium from the surrounding ep-
ithelium. The diagnostic changes characteristic of
mild dysplasia are confined to the lower half of the
epithelium, and with increasing grade, the atypi-
cal cells involve and replace the entire thickness
of the epithelium. In CIS, no cellular maturation
is observed on the epithelial surface.3,4 Several se-
ries reported in the literature demonstrated that in-
creasing grades of dysplasia were associated with
increasing risk of developing ESCC.5 Wang et al.6
tried to identify the clinically relevant histologi-
cal precursors of ESCC, analyzing a cohort of 682
endoscoped patients biopsied at baseline and fol-
lowed for 13.5 years. The authors concluded that
Figure 1. (A) Low- and (B) high-grade squamous intraepithelial neoplasia (hematoxylin–eosin, original magnification 40×).
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Figure 2. Low (A) and high (B) grade glandular dysplasia (hematoxylin–eosin, original magnification 40×).
squamous dysplasia and carcinoma in situ were the
only histological lesions associated with a signifi-
cantly increased risk of developing ESCC, and that
increasing grades of dysplasia were strongly asso-
ciated with increasing risk, indicating that the his-
tological grading was clinically meaningful. In ad-
dition, recent advances in molecular biology7 em-
phasize the strict sequence LG-IEN–HG-IEN in the
development of invasive cancer, depending on ge-
netic and epigenetic changes that parallel the his-
tological modifications observed in the neoplastic
progression. For example, Liu et al.8 characterized
the molecular events in the carcinogenesis of ESCC,
analyzing precancerous and cancerous tissues re-
sected from 34 esophageal cancer patients in which
he evaluated the extent of LOH in 16 microsatel-
lite markers on different chromosome regions. The
authors found that the overall frequency of LOH at
the 16 microsatellite loci was significantly increased
as the pathological status of the resection specimens
changed from LGD to HGD and ESCC, indicating
that tumorigenesis of the esophageal squamous ep-
ithelia is a progressive process involving a series of
molecular alterations. As the alterations accumulate
to a certain degree, the cell morphology and behav-
ior undergo a radical change, leading tomalignancy.
In our experience from 2000 to 2012, we detected
204 cases diagnosed as invasiveESCC. In33 cases,we
had available esophageal biopsies performed before
the histological diagnosis of cancer; in all cases we
detected the LG-IEN–HG-IEN sequence, emphasiz-
ing the concept that it is mandatory: a progressive
passage from LGD to HGD in the progression to-
wards invasive cancer.
2. Can low-grade glandular dysplasia
give rise directly to invasive cancer?
Vincenzo Villanacci and Marianna Salemme
villanac@alice.it
Dysplasia can be defined as an “unequivocal, neo-
plastic transformation of the epithelium excluding
all reactive changes”11 showing histological find-
ings and expression of the DNA damage that pre-
cedes malignancy. On the basis of this definition,
dysplasia must be considered a neoplastic process
that cannot regress. In the context of BE, glandu-
lar dysplasia is then classified into two important
categories, namely LGD and HGD, on the basis of
accurate histological features (Fig. 2). LGD shows
crypts with relatively preserved architecture or only
minimal distortion, and stratified atypical nuclei
(hyperchromatic, with an irregular contour and a
dense chromatin) limited to the basal portion of the
cell cytoplasm.Withprogression toHGD, thedegree
of cytological and architectural complexity becomes
more advanced,with crypt budding, branching, and
marked crowding. Cytologically, cells show marked
nuclear pleomorphism and irregularity of contour,
loss of cell polarity, and a higher number of atypical
mitoses with a typical full-thickness nuclear strati-
fication. The recognition of these pathological con-
ditions depends mostly on an adequate biopsy sam-
pling andanaccurate diagnostic interpretation from
the pathologist. First of all, a correct biopsy sam-
pling is of paramount importance, mainly because
of the “patchy” distribution of the dysplasia. Sev-
eral authors suggest different types of sampling;12,13
however, in our experience, at least one biopsy every
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Table 2. Histological disease progression of Barrett’s
esophagus patients
Histological
progression in BE Dysplasia Dysplasia + cancer
LGD 22 3
HGD 1 6
LGD + HGD 17 17
Note: In our experience, among 537 cases with histo-
logical diagnosis of BE between 2000 and 2012, during
a follow-up period of 12 years, 72 patients showed his-
tological progression of the disease. Of these, 40 patients
developed dysplasia, while 26 patients developed dyspla-
sia and subsequently cancer. The table shows in 17/40
(42.5%) patients with dysplasia the presence of the se-
quence LGD/HGD, while in 17/26 (65%) patients with
dysplasia and subsequently cancer the presence of the se-
quence LGD/HGD/cancer.
2 cm in Barrett’s area above the Z line must be ob-
tained.Unfortunately, notwithstanding an adequate
biopsy sampling, there is a high degree of subjectiv-
ity in diagnosis and grading of dysplasia in BE: Reid
reported a 56–61% inter-observer agreement be-
tween categories named negative/indefinite for dys-
plasia, LGD/HGD, and intramucosal carcinoma.14
Several series confirmed this problem,15 empha-
sizing the concept that “accurate interpretation re-
quires an experiencedpathologist.”16 Nowadays, the
existence of the sequence LGD–HGD–invasive can-
cer is also supported by IHC andmolecular biology.
In our experience, in particular, the application of
immunohistochemical techniques revealed the ex-
istence of two pathways in the development of dys-
plasia in the context of BE: on one side, dysplastic
cells show positivity for p16 and negativity for p53
andHER2; on the other side, dysplastic cells express
p53 and HER2 and lack of p16 expression. These
results reflect two different underlying molecular
pathways. However, it is important to remember
that “the results obtainedwith additional techniques
must be interpreted with caution; the simple mor-
phological recognition of dysplasia in endoscopic
biopsies remains important for the management of
the cancer risk” (Karel Geboes). We also demon-
strated the existence of the strict sequence LGD–
HGD–invasive cancer. We selected 537 cases with
histological diagnosis of BE performed through an
adequate biopsy sampling13 between 2000 and 2012,
analyzing for each patient all subsequent histologi-
cal reports performed during a follow-up period of
12 years. Seventy-two patients showed histological
progression of the disease; among these 40 patients
developed dysplasia, while 26 patients developed
dysplasia and subsequently cancer. Seventeen of 40
(42.5%) patients with dysplasia showed the pres-
ence of the sequence LGD–HGD,while 17/26 (65%)
patients with dysplasia and subsequently cancer re-
vealed the presence of the sequence LGD–HGD–
cancer, emphasizing the concept that LGD cannot
give rise directly to invasive cancer, but there is a
morphological sequence LGD–HGD–cancer, con-
firmed also by IHC andmolecular biology (Table 2).
3. Mutational spectra of Barrett’s
esophagus and adenocarcinoma
Marco Matejcic and M. Iqbal Parker
iqbal.parker@icgeb.org
Esophageal cancer is the eighth most common can-
cer worldwide and ranks as the sixth most com-
mon cause of cancer-related death owing to the late
symptomatic presentation resulting in a low 5-year
survival prognosis.17
EAC, the predominant subtype in developed
countries, typically arises from glandular cells lo-
cated in the distal one-third of the esophagus or
gastroesophageal junction (GEJ), and is primarily
associated with obesity, GERD, and BE. The inci-
dence of EAC has rapidly increased over the past
three decades, especially indeveloped countries, and
ismore commonamongCaucasianmenover the age
of 60 (Table 3). The rise in incidence rates is likely a
secondary effect owing to an increase in the preva-
lence of obesity. However, the incidence rates vary
widely from one area to another within the same
country or ethnic group.17 It is nowwidely accepted
that EAC develops along a sequence of phenotypic
and genetic alterations that evolve from metaplasia
through dysplasia to carcinoma.
BE is the only well-recognized premalignant con-
dition for the development of EAC. BE is defined as
a metaplastic transformation occurring at the distal
esophagus, where esophageal squamous epithelium
is replaced by columnar epitheliumwith goblet cells.
Patients with BE have a 30- to 60-fold higher risk of
developing EAC than the general population; how-
ever, only 1–5% of these cases progress to dysplasia,
and the risk of cancer increases significantly with
the grade of dysplasia.18
100 Ann. N.Y. Acad. Sci. 1325 (2014) 96–107 C© 2014 New York Academy of Sciences.
Appelman et al. Progression of esophageal dysplasia to cancer
Table 3. Adenocarcinoma of the esophagus: epidemiology, etiology, and symptoms
Age Mostly> 60 years
Sex Male dominant
Location Distal one-third of the esophagus or gastroesophageal junction
Distribution Western countries, middle or upper socioeconomic status
Risk factors BE, GERD, obesity, tobacco smoking, lower esophageal sphincter–relaxing drugs, epidermal
growth factor polymorphism, low intake of fiber, high intake of dietary fat and animal
protein, nitrosative stress
Protective factors Helicobacter pylori infection, aspirin, non-steroidal anti-inflammatory drugs (NSAIDs),
cyclooxygenase-2 inhibitors, high consumption of fruit and vegetables, diets rich in fiber
Symptoms Progressive dysphagia, odynophagia, halitosis, weight loss, chest pain
GERDis themajor risk factor forBE.Patientswith
GERD have significantly more gastric acid and bile
in their esophagus. The low pH, as well as the bile
salts, induces expression of COX-2, which is a key
enzyme of the arachidonic acid biosynthetic path-
way. COX-2 catalyzes the conversion of arachidonic
acid into various prostaglandins including PGE2,
which induces proliferation of BE cells and raises
the probability for these cells to accumulate replica-
tion errors.19 PGE2 also inhibits tumor surveillance
by inhibiting natural killer cell activity. COX-2 may
also induce the production of ROS, resulting in ox-
idative stress and subsequent oxidative DNA dam-
age that could contribute to carcinogenesis.19
The presence of genetic mutations is another im-
portant factor leading to EAC. The most common
chromosomal alterations found in BE include allelic
losses at chromosomes 4q, 5q, 9q, 18q, 7a, and 14q,
as well as gains at 8q, 20q, 2q, 7q, 10q, 6p, 15q, and
17q.20 Apart from gross chromosomal alterations,
specific mutations in genes involved in cell cycle
control (i.e., p53, p16, Rb, cyclin D1, and c-myc)
have been reported. Accordingly, changes in the cell
cycle of the affected epithelial cells, such as an in-
creased number of cells in S phase (corresponding
to DNA synthesis) and G2 phase (pre-mitosis), have
been described inBEpatients.21 Genomic instability
in BE is also represented by widespread LOH, point
mutations, alterations in microsatellite alleles, and
epigenetic changes including hypermethylation of
promoter regions in genes. Furthermore, polymor-
phisms of the epidermal growth factor (EGF) gene
have been associated with higher serum levels of
EGF and an increased risk of EAC, particularly in
patients with BE.22 The major events and genetic
alterations associated with the development of BE
and EAC are shown in Figure 3.
Obesity, which results from high caloric con-
sumption and energy imbalance, appears to be a
risk factor for the development of GERD and sub-
sequent EAC.23 How overnutrition leads to GERD
development is still uncertain; however, obesity in-
creases circulating levels of many steroid hormones
and insulin-like growth factor-1 (IGF-1). The bind-
ing of IGF-1 to its receptor, IGF-1R, could transduce
signals through several intracellular pathways, stim-
ulating themalignant transformation of various ep-
ithelial and mesenchymal cells and protecting these
cells from apoptosis.19
Tobacco smokinghasbeenassociatedwithamod-
erately increased risk of EAC, particularly in patients
with BE. However, the strength of this association
appears to beweak compared to the associationwith
ESCC.19 Antioxidants present in fruits and vegeta-
bles seem to have a protective effect, whereas low in-
take of fiber andhigh intakeof dietary fat and animal
protein appear to increase the risk of BE.19 Exposure
to nitroso compounds derived from dietary sources
has also been associated with the development of
EAC.24
Finally, some studies have suggested that Heli-
cobacter pylori infection, and CagA strains in par-
ticular, may be associated with a protective effect
against the development of BE and progression to
EAC, probably by decreasing GERD.19 The postu-
lated mechanism is through the ability of H. pylori
to induce atrophic gastritis, which likely increases
intragastric ammonia production.25
Despite the wide knowledge in the etiology of
esophageal cancer, the precise causes of EAC have
not yet been identified, and the reasons for the
trend of increasing EAC in Western countries re-
main largely unexplained. Nevertheless, some data
suggest that interactions between risk factors may
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Figure 3. Temporal relationship between genetic alterations and the development of EAC. The succession of histopathological
stages starting from normal epithelium and leading to adenocarcinoma is shown. Cellular alterations associated with these various
stages are described in the boxes. The thick black arrows in the boxes signal increases in the S-phase fraction, the G-phase fraction,
aneuploid cells, and the G2-phase fraction.
bemore important in the development of EAC than
the individual risk factors themselves.26 Future di-
rections include the need to stratify BE patients for
esophageal cancer risk by the use of genetic sus-
ceptibility data and biomarkers, which would al-
low the identification of patients who are truly at
risk for malignant generation in order to imple-
ment treatment and prevention strategies for these
patients.
4. In Barrett’s mucosa, is
p53-immunoreactive low-grade dysplasia
at higher risk than non-immunoreactive
low-grade dysplasia for progressing to
carcinoma?
Henry D. Appelman
appelman@umich.edu
In order to answer this question, we have to answer
two others. First, is the histologic diagnosis of LGD
reproducible? Second, if it is reproducible, then is
positive p53 staining of the dysplastic epithelium a
better predictor of progression to carcinoma than
negative staining?
In regard to the first question, the standard di-
agnoses used for biopsies of Barrett’s mucosa in-
clude no dysplasia, LGD and HGD, invasive adeno-
carcinoma, and an indeterminate category referred
as “indefinite for dysplasia,” in which the patholo-
gist viewing the case cannot decide if the changes are
those of dysplasia or of regeneration. Unfortunately,
the criteria for each diagnosis are not clear cut, so
reproducibility of diagnoses may be poor. Certainly,
something given the name of “indefinite for dys-
plasia” has a built-in lack of reproducibility. Several
studies of dysplasia have found that reproducibil-
ity among even highly experienced pathologists is
best at the highest end of the dysplastic spectrum,
namely HGD and carcinoma, while it is poorest at
the LGD end. Since there is no consistent definition
of LGD, it is to be expected that the definitions in
the literature and in the textbooks of gastrointestinal
pathology will not be the same. The published defi-
nitions of LGDare filledwith nonspecific, unhelpful
words such as slightly, reduced, larger, normal,mild,
more atypical, irregular, inconspicuous, and marked
decrease.
In the Department of Pathology at the Univer-
sity of Michigan, three of us who handled most of
the esophageal biopsy consultation cases indepen-
dently classified the changes in every case.We found
that agreement among the three of us in the diag-
nosis of LGD only occurred about one-fourth of
the time. In contrast, we all agreed on the diagno-
sis of HGD 50% of the time, on carcinoma 75%
of the time, and on non-dysplasia over 80% of the
time.
In a study from the Netherlands, biopsies diag-
nosed by different pathologists in six community
hospitals as LGD in 147 patients were reviewed by
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two expert pathologists.15 This raises an important
issue, namely what qualifies a pathologist as an ex-
pert. There is no examination that certifies that a
pathologist is expert in diagnosing LGDor any other
epithelial change in Barrett’s mucosa, or any other
mucosa for that matter. Regardless, these two ex-
pert pathologists downgraded 85% of the LGD di-
agnoses to either negative or indefinite for dysplasia.
For the 15% in which they confirmed the diagnosis
of LGD, there was an 85% cumulative risk of pro-
gression to HGD or carcinoma in 109 months. In
contrast, for the 85% of the cases that were down-
graded, there was only a 5% risk of progression in
107 months. In another study from four U.S. cen-
ters covering 618 patients, 156 cases were diagnosed
as LGD.27 There was no central pathologist review
of these cases, a problem with this study, because
of the lack of reproducibility in the LGD diagnosis.
Nevertheless, the authors found that progression to
carcinoma from LGDwas not significantly different
in these 156 patients compared to the entire group
of 618 patients. Unfortunately, these two studies are
not totally comparable because they were not per-
formed in the same way.
P53 is a tumor suppressor gene, a transcription
factor important in cell cycle regulation. The en-
coded protein is nuclear, so the immunostain is
easy to interpret. Several studies have looked at p53
in Barrett’s mucosa. In one study of 17 cases with
p53 mutations, there was a progressive increase in
mutations from nondysplastic to LGD to HGD.28
In another study, progression from indefinite and
low-grade dysplasia correlated with positive p53
staining.29 There was a progressive increase in stain-
ing percentage from negative to LGD to HGD, but
in this study there was actually a decrease in staining
in carcinomas. The authors felt that p53 positivity
helped in the diagnosis of LGD. In another study,
p53+ LGDwasmuchmore likely progress than p53–
LGD in 16 patients.30 There are some problems
with this study. All the cases were reviewed by three
pathologists, but they all agreed on the LGDdiagno-
sis in only four of the cases. Furthermore, the mean
follow-up time for progressors was only 11 months,
suggesting that at least some of the reported pro-
gressors actually had prevalent HGD or carcinoma
rather than progression. In a 2013 study from the
Netherlands covering 635 Barrett’s patients, an in-
creased rate of progression occurred in p53+ LGD
compared to p53– LGD.31 However, in the same
study, p53+ nondysplastic epithelium also had an
increased risk of progression.
Based on these somewhat disparate studies, it
seems that patients with p53-immunoreactive LGD
are at higher risk for progression than those with
p53–non-immunoreactive LGD, although this is
clouded by the lack of reproducibility for the LGD
diagnosis. There is recent mention of p53 immuno-
staining being considered as an adjunct to routine
histopathologicdiagnosis, hoping to improve thedi-
agnosis of dysplasia inBarrett’smucosa.As an exam-
ple, in the latest Barrett’s guidelines from the British
Society of Gastroenterology, this recommendation
is included: “The addition of a p53 immunostain to
the histopathological assessment may improve the
diagnostic reproducibility of a diagnosis of dysplasia
in Barrett’s oesophagus and should be considered as
an adjunct to routine clinical diagnosis.”32 However,
diagnoses of dysplasia are histologic diagnoses, not
immunohistochemical diagnoses. Positive staining
may improve recognition of those patients who are
at risk to progress, but this may have nothing to do
with the diagnosis of LGD.
5. Do lectins have a role in the
progression to adenocarcinoma?
Paul E. Swanson
paul.swanson@cls.ab.ca
Lectins are plant or animal proteins with high sen-
sitivity and variable specificity for selected glycosyl
moieties. These proteins are typically membrane
bound and function locally as receptors. They canbe
employed as probes for glycosylated biomarkers in
serum, cell fractions, and fresh or fixed tissue sam-
ples using chromatographic applications, immuno-
fluoresence (when labeled with appropriate
reporter molecules) and enzyme-linked histochem-
ical detection systems (when biotinylated or when
lectin-specific antibodies are used as secondary
probes). An evolving understanding of the complex
glycoprotein milieu in the normal and diseased
esophagus paints an intriguing picture that suggests
a re-emergent role for lectins in the diagnosis
and management of BE and BE-associated EAC.
This brief commentary will assess the value of
quantitative serum glycomics to diagnosis and
surveillance in BE patients and address the poten-
tial utility of fucosyl-, N-acetyl-d-glucosaminyl-,
and N-acetyl-d-galactosaminyl-specific lectin
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histochemistry in the evaluation of BE, both
ex vivo, through analysis of standard formalin-
fixed, paraffin-embedded tissue samples and in
vivo, using lectin-based endoscopic visualization
techniques.
Serum glycomics
The local production of glycoproteins in normal
and diseased tissues is reflected in a complex spec-
trum of glycosylated molecules in serum. While it
is unlikely that any single glycan in serum will be
specific for a given tissue or disease, patterns of
aberrant glycosylation in disease states may be dis-
proportionately overrepresented in serum. Using a
mass spectrometry–based evaluation of N-glycans
that are released enzymatically from serum glyco-
protein fractions obtained from patients with BE,
BE with HGD, and BE-associated EAC, Mechref
et al.33 demonstrated by principal-component anal-
ysis that these patient populations can, to varying
degrees, be separated fromeach other and fromnor-
mal controls. Among the many glycosylation pat-
terns identified, a limited subset of glycan structures
reliably predicted the diagnosis of EAC when com-
pared to controls. Similarly, BE–HGD could be dis-
tinguished from both controls and EAC, but in gen-
eral with lesser accuracy. The differences between
BE and BE–HGD were not diagnostically reliable,
although BE glycomic profiles remained distinct
from controls. The relevance of these differential
profiles to biomarker discovery is a subject of ongo-
ing investigation. Notably, the distinct repertoire of
altered glycans from EAC was significantly depleted
of fucosyl moieties when compared with controls,
though many of the glycans of interest in this study
contained core and terminal fucose residues. In-
terestingly, some of the latter may be of particular
importance to the progression from BE through
BE–HGD to EAC. Applying lectin-affinity chro-
matography to serum samples using the fucosyl-
specific lectins Aleuria aurantia lectin (AAL) and
Lotus tetragonolobus agglutinin (LTA), Mann et al.34
identified a subset of proteoglycans that demand
further scrutiny in this regard, including fetuin B, a
cystatin that is somewhatoverexpressed inBE–HGD
relative to disease-free esophagus, but significantly
increased in EAC; and elastin microfibril interface
located protein 2 (EMILIN-2), an extracellular ma-
trix glycoprotein that is involved in activation of
the extrinsic pathway of apoptosis and inhibits cell
growth. It is increased in BE–HGD and EAC when
compared to control samples.
Lectin tissue histochemistry
The relative depletion of fucosyl residues in the
BE to EAC sequence is immediately applica-
ble to routinely processed biopsy samples. Initial
studies by Bird-Lieberman et al.,35 using a fucosyl-
specific lectin derived fromAspergillus oryzae (AOL,
a lectin-like AAL with broad specificity for fucosy-
lated glycoproteins36), confirmed the expectation
that decreased histochemical staining (measured as
intensity and distribution of AOL staining in four
cell compartments: global cell membranes, apical
cell membranes, epithelial mucous globules, ep-
ithelial cytoplasm, and all membranes) may predict
the transition from BE to EAC. Similar observa-
tionsweremadewith the sialyl-selective wheat germ
agglutinin (WGA, from Tritium vulgaris, a lectin
that also selectively bindsN-acetyl-d-glucosamine),
though the relationship between loss ofWGA stain-
ing and disease progression was less pronounced.
These finding have led to the formulation of a robust
risk-stratification biomarker panel for progression
from BE to EAC that combines AOL stain results
with LGD and DNA ploidy.36 Among other lectins,
the N-acetyl-d-galactosaminyl–selective agglutinin
from H. pomatia (the edible Burgundy snail) selec-
tively labels glycans that, when present or increased
in number,may be associatedwith progression from
locally invasive esophageal disease tometastasis.37,38
Endoscopic lectin-enhanced visualization of
esophageal mucosa
Given the expectation that certain glycanswill be de-
creased in BE, BE–HGD, and EAC compared to nor-
mal mucosa, selective lectin labeling of esophageal
mucosa in BE patients may prove to be a useful
guide for traditional biopsy techniques. Although a
fucosyl-selective lectin would be ideal in this set-
ting, work to date has employed WGA, in large
part because this lectin is common in food prod-
ucts and thus carries minimal risk for topical or sys-
temic adverse effects. Since glycomic studies suggest
that sialyl residues are not significantly decreased
in the progression from BE to EAC, the utility
of WGA in this context is more likely due to its
affinity for N-acetyl-d-glucosamine. As shown by
Bird-Lieberman et al.,39 the topical application of
fluorescein-WGA readily defines areas of decreased
emission when viewed endoscopically under UV
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light, areas that reproducibly map to biopsy-proven
BE–HGD and EAC. As an adjunct to confocal laser
endomicroscopy,40,41 lectin labeling could reason-
ably be expected to increase the efficiency of both
scanning for and targeting of suspicious lesions,
though this is, for the moment, an untested con-
jecture.
Conclusions
Serum glycomic analyses identify patterns of abnor-
mal glycoprotein expression that distinguish ade-
nocarcinoma patients from normal controls. Much
of this difference may be due to selective loss of
fucosylated glycans, an observation that has been
successfully applied to tissue-based lectin histo-
chemical studies of theprogression fromBE through
BE–HGD to EAC. Fluorescently labeled lectins may
also be useful probes for the endoscopic surveillance
of BE, an intriguing observation that is potentially
applicable to esophageal endomicroscopy.
6. Does racemase/AMACR
immunoreactivity predict increased risk of
esophageal adenocarcinoma in Barrett’s
esophagus?
Robert H. Riddell
rriddell@mtsinai.on.ca
AMACR is present in many dysplasias and carcino-
mas, although it has been used histologically in the
diagnosis of prostatic carcinoma owing to its high
sensitivity and specificity (Fig. 4A). It also became
apparent that dysplastic mucosa in ulcerative colitis
may be AMACR positive with IHC42 and that this
may be of predictive value in determining patients
at high risk43 (Fig. 4B). Inevitably, the question was
also reapplied to ask whether AMACR could be of
similar value in identifying patients at highest risk
for BE,1 and a variety of patients suggested that
it may be of value in intestinal-type dysplasia but
likely not in foveolar dysplasia in BE44–47 (Fig. 5).
Its sensitivity came into question, as occasionally
non-dysplastic mucosa would also stain (Fig. 5C).
However, these largely lacked the power to answer
the question.
However, in a study using theNational Registry in
the Netherlands,48 among a cohort of 720 patients
in the Barrett’s registry, 635 patients were enrolled.
Those with no neoplastic progression (586; 92%)
were compared with those in whom neoplastic pro-
gression occurred (HGD or EAC in 49% or 8%,
A B
Figure 4. (A) Red staining AMACR immunoreactivity in pro-
static carcinoma infiltrating between non-dysplastic prostatic
glands highlighted by black-staining keratin. (B) Barrett’s intra-
mucosal carcinoma (top) staining uniformly red.
respectively). Those in the control groupwere endo-
scoped every 3 years, while those with LGDwere en-
doscoped annually, undergoing a mean of four en-
doscopiesover ameanof 6.6 years.AMACRIHCwas
performed on paraffin material of all surveillance
endoscopies of patients who developed LGD, HGD,
or EAC. In patients without dysplasia, AMACR IHC
was performed on biopsies of a random surveillance
endoscopy. Scoring was carried out on the worst
biopsies, which were graded as 0, mild, or strong
immunoreactivity.
No AMACR expression was seen in 47% of the
biopsy series, mild AMACR staining was seen in
48%, and 5% had strong immunoreactivity. Mild
AMACR expressionwas seen in 46%of biopsy series
without dysplasia, 53% of biopsy series with LGD,
A B
C D
Figure 5. High-gradeBarrett’s dysplasia (hematoxylin–eosin).
(B) foveolar dysplasia with no immunoreactivity. (C) Intesti-
nal dysplasia with brown-staining AMACR immunoreactivity
left and right, but also in the non-dysplastic mucosa (cen-
ter). (D)Low-grade intestinal dysplasia showingbrown-staining
immunoreactivity with ACMACR antibody.
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64% of biopsy series with HGD, and 57% of biopsy
serieswithEAC. StrongAMACRexpressionwas also
seen in 3% of biopsy series without dysplasia, 10%
of biopsy series with LGD, 27% of biopsy series with
HGD, and 14% of biopsy series with EAC. Although
mildAMACRexpressionwas associatedwith a trend
towards an increased risk of neoplastic progression
(adjusted RR 1.6; 95% CI 0.9–3.1), the risk was es-
pecially elevated with strong AMACR expression
(adjusted RR 4.8; 95% CI 1.9–12.6). After adjust-
ing for histological diagnosis, only strong AMACR
expression remained associated with a significantly
increased risk of neoplastic progression (adjusted
RR 1.4; 95% CI 0.8–2.6 and 3.3; 95% CI 1.3–8.4,
respectively). The sensitivity of AMACR expression
for predicting neoplastic progression was 67% with
a specificity of 50%, PPV was 11%, and NPV was
97%. Of 41 (6%) patients with strong AMACR ex-
pression during follow-up, nine (22%) eventually
developed HGD or EAC with an incidence rate of
7.1 per 100 patient years. The sensitivity of strong
AMACR expression for predicting neoplastic pro-
gression was 10% with a specificity of 96%, a PPV
of 22%, and a NPV of 93%.
These datamake it abundantly clear that AMACR
expressionhas a degree of predictability, but that it is
not sensitive, and that non-dysplastic biopsies can
have variable immunoreactivity. Once the cost of
the test is taken into account, this limited value is
not worth the cost of the test.
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